Abstract:The advancement of transoral surgical techniques for the management of oropharyngeal carcinomas has raised questions about how adjuvant therapy can best be integrated. Some of these questions have come from the application of established oncologic principles of adjuvant therapy, and some are unique to the evolving experience with transoral surgery and in particular with the recent advancement of robotic surgery. It is important for all members of the multidisciplinary treatment team to have a clear understandi… Show more
“…Surgery, followed by a shortened course of radiation therapy without chemotherapy, may have fewer late toxic effects than definitive chemoradiotherapy. [33][34][35] However, the treatment decision is partly dependent on accurate pretreatment detection of ECS. Patients with ECS identified after TORS and neck dissection will still require adjuvant chemotherapy and near full-level radiation therapy, attenuating the potential advantages of TORS.…”
Computed tomography cannot be used to reliably determine the presence of pathologic ECS. Radiologic findings suggestive of ECS should not be relied on for treatment planning in squamous cell carcinoma of the head and neck.
“…Surgery, followed by a shortened course of radiation therapy without chemotherapy, may have fewer late toxic effects than definitive chemoradiotherapy. [33][34][35] However, the treatment decision is partly dependent on accurate pretreatment detection of ECS. Patients with ECS identified after TORS and neck dissection will still require adjuvant chemotherapy and near full-level radiation therapy, attenuating the potential advantages of TORS.…”
Computed tomography cannot be used to reliably determine the presence of pathologic ECS. Radiologic findings suggestive of ECS should not be relied on for treatment planning in squamous cell carcinoma of the head and neck.
“…17 Can we safely exclude the primary site from our radiation field in certain situations, as has been suggested by Quon et al? 18 We have previously reported on 69 patients with oropharyngeal cancer that were treated with TLM alone. 19 Forty-four of the 69 patients were stage III or IV and there were only 3 local recurrences.…”
Background
The purpose of this study was to report the treatment outcomes of patients with advanced oropharyngeal cancer treated with transoral laser microsurgery (TLM) followed by radiation therapy (RT) at Mayo Clinic in Arizona.
Methods
A retrospective study of 80 patients treated from January 1, 2000 to November 7, 2011 was performed. All patients had stage III/IV oropharyngeal tumors and underwent TLM with neck dissection. Adjuvant RT was then given. Thirty-seven patients received concurrent adjuvant chemotherapy. The primary outcome was locoregional control.
Results
Median follow-up was 47.3 months (range, 9.7–139.2 months). The 3-year locoregional control, recurrence-free survival, and overall survival rates were 98.6% (95% confidence interval [CI], 91% to 100%), 91.1% (95% CI, 81% to 96%), and 93.7% (95% CI, 84% to 98%), respectively. There were a total of 5 treatment failures, 1 regional and 4 distant. Twenty-six patients underwent neck only RT with exclusion of the primary site.
Conclusion
TLM followed by RT for advanced oropharyngeal cancer results in excellent locoregional control rates.
“…In the case of relative indications for adjuvant treatment, the risks and benefits of treatment vs observation are discussed in detail with the patient. Quon et al 8 have previously described the rationale and approach for postoperative irradiation following TORS.…”
As the only modality used for treatment of pathologically low-risk OSCCs, TORS provides high local control and is associated with low surgical morbidity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.